PercayAI and the Collaboration
PercayAI is a startup based in St. Louis and owned by investment firm Kingdom Capital made up of a diverse team of computer scientists, computational biologists, chemists, and life-science executives working toward changing the way the drug discovery process works. PercayAI plans to do this through the use of its augmented intelligence technology. This augmented intelligence technology was created with help from GTAC, with whom the company still maintains a strong working relationship. This is where the collaboration with the Washington University School of Medicine comes into play. Through their collective efforts, the two plan to hopefully find more effective drug combinations that will fight against the COVID-19 virus.
Their combined research will see PercayAI using their augmented intelligence software to sparse through and process the massive amount of clinical and genomic data that Washington University’s Institute for Informatics and McDonnell Genome Institute currently have. Once this has been completed, the augmented intelligence will have come up with plenty of results, including new potential drug treatments. Researchers from Washington University, along with computational scientists from PercayAI, will then determine the possibilities of using these drugs in practice. Next, their findings will then be used or possibly used in research studies, directly testing the effectiveness of different drug combinations for combatting COVID-19. If proven to be successful in these research studies, the drug combinations found by PercayAI could legitimately see practical use in helping the world quell the ongoing pandemic. Beyond this combined effort, the collaboration between PercayAI and Washington University represents another major partnership for life science and healthcare — a relatively new phenomenon.
The Mix of Life Science and Healthcare
PercayAI and Washington University are a sign of the positive trend between interdisciplinary studies such as life science and healthcare. Especially during dire times, such as, say, a pandemic, the collaboration between essentially two different areas of work becomes increasingly important when their work together could literally save perhaps millions of lives. The use of deep learning algorithms and clinical research results in more holistic outcomes as a natural consequence of the two fields working in tandem. In general, the two fields have been moving more toward higher-level technologies, expediting and expanding the results and potential conclusions of high-level research. In particular, the healthcare industry is increasingly becoming open to using more technology and dense data to solve or at least contribute to solving the many different issues facing the healthcare world, especially right now, when every possible tool available should be used.
PercayAI is home to significant and important augmented intelligence technology that has immense upside potential. Their very diverse team of skilled workers, all specializing in slightly different fields, give the company a serious leg up against much of who could be considered their competition. Thus, their new collaboration with Washington University is a critical move. With the dense amount of genomic and clinical data they have in their possession, using augmented intelligence to sparse through it to find possible drug treatments for COVID-19 could lead to greatly beneficial results. Collaborations like this happening at a higher frequency certainly help boost the odds of more effective treatments being discovered. These joint efforts could lead to better preventive measures being put in place, and perhaps even legitimate cures that could help end the pandemic once and for all.
About the Author
Tom Price is a writer focusing on Entertainment and Sports Features. He has a degree from NYU in English with a minor in Creative Writing. He has been previously published for Washington Square News, Dignitas, CBR, and Numbers on the Boards.